Research Interests:
Drugs for tropical diseases; drug development and policy for medical countermeasures for biodefense; clinical trial design

Selected Publications:
Meyerhoff A. (1999) The FDA approval of AmBisome for the treatment of visceral leishmaniasis. Clin Infect Dis. 28:42-8.

Meyerhoff A, Parise M. (2000) The availability and use of parenteral quinidine gluconate for severe falciparum malaria. Morb Mortal Wkly Rep. 49:1138

Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes J, Jahrling P, Ksiazek T, Johnson K, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K. (2002) Hemorrhagic fever viruses as biological weapons. JAMA 287: 2391-406.

Meyerhoff A, Albrecht R, Meyer J, Dionne P, Higgins K, Murphy D. (2004) The FDA approval of Cipro for post-exposure inhalational anthrax. Clin Infect Dis. 39:303-8.

Meyerhoff A. Challenges in drug development: Biological agents of intentional use In: New Drug Applications: Regulatory and Scientific Principles for Clinical Pharmacology and Biopharmaceutics, Sahajwalla, C, ed. Marcel Dekker, 2004.

Meyerhoff A. Give Project BioShield More Expertise. Washington Post. April 9, 2006.

Return to Faculty Home